Early switch from run-in with targeted to immunotherapy in advanced BRAF^V600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ABSTRACT:

Background

Optimal sequencing of immune checkpoint inhibitors (ICIs) and targeted therapies (TTs) in BRAF^V600-positive advanced melanoma should achieve rapid tumour control and durable progression-free survival (PFS), translating into prolonged overall survival (OS).

Patients and methods

The 1 : 1 randomised phase II ImmunoCobiVem trial compared-after a 3-month run-in phase with vemurafenib (VEM, 960 mg twice daily) and cobimetinib (COB, 60 mg daily days 21-28, q4w)-continuous VEM + COB until disease progression (PD1) and second-line atezolizumab (ATEZO, 1200 mg, q3w) in arm A versus early switch to ATEZO after run-in, followed by crossover to VEM + COB at PD1, in arm B. PFS from the start of run-in until PD1 was the primary endpoint (PFS1); secondary efficacy end

SUBMITTER: Livingstone E 

PROVIDER: S-EPMC12136786 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature